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Abstract
The INhibitor of Growth tumor suppressors (ING1-ING5) affect aging, apoptosis, DNA repair and tumorigenesis. Plant
homeodomains (PHD) of ING proteins bind histones in a methylation-sensitive manner to regulate chromatin structure.
ING1 and ING2 contain a polybasic region (PBR) adjacent to their PHDs that binds stress-inducible phosphatidylinositol
monophosphate (PtIn-MP) signaling lipids to activate these INGs. ING1 induces apoptosis independently of p53 but other
studies suggest proapoptotic interdependence of ING1 and p53 leaving their functional relationship unclear. Here we
identify a novel ubiquitin-binding domain (UBD) that overlaps with the PBR of ING1 and shows similarity to previously
described UBDs involved in DNA damage responses. The ING1 UBD binds ubiquitin with high affinity (Kd,100 nM) and
ubiquitin competes with PtIn-MPs for ING1 binding. ING1 expression stabilized wild-type, but not mutant p53 in an MDM2-
independent manner and knockdown of endogenous ING1 depressed p53 levels in a transcription-independent manner.
ING1 stabilized unmodified and six multimonoubiquitinated forms of wild-type p53 that were also seen upon DNA damage,
but not p53 mutants lacking the six known sites of ubiquitination. We also find that ING1 physically interacts with
herpesvirus-associated ubiquitin-specific protease (HAUSP), a p53 and MDM2 deubiquitinase (DUB), and knockdown of
HAUSP blocks the ability of ING1 to stabilize p53. These data link lipid stress signaling to ubiquitin-mediated proteasomal
degradation through the PBR/UBD of ING1 and further indicate that ING1 stabilizes p53 by inhibiting polyubiquitination of
multimonoubiquitinated forms via interaction with and colocalization of the HAUSP-deubiquitinase with p53.
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Introduction
The INhibitor of Growth 1 (ING1) type II-tumor suppressor [1]
is down-regulated in many human malignancies [2,3]. It is one of a
family of 5 genes (ING1 to ING5), several of which generate
multiple protein isoforms, such as p47
ING1a (ING1a), p33
ING1b
(ING1b) and p24
ING1c (ING1c). ING1b is the major isoform
expressed in human cells [2] and is involved in tumorigenesis [2–
4], senescence [5], apoptosis [6] and DNA repair [2,3,7].
Hereafter, reference to ING1 will mean ING1b unless otherwise
noted. INGs function through direct interaction with other
proteins [8], primarily in the nucleus [9], where they regulate
chromatin structure [10]. INGs bind lamin A via their unique
lamin interaction domain (LID) contributing to the Hutchinson-
Gilford progeria-syndrome phenotype [11]. The most highly
conserved domain of the ING proteins is their plant homeodo-
main (PHD), a form of zinc finger. PHDs in INGs interact with
core histone proteins in a histone methylation-sensitive manner,
implicating ING proteins as interpreters of the histone epigenetic
code [12–14]. This mechanism is well-conserved considering that
progressive methylation of yeast histone H3K4 also increases ING
histone affinity [14–16]. ING2 directs the acetylation of histone
H3-residue K14 [16], suggesting that INGs regulate the histone
code by linking histone methylation to -acetylation. Additionally,
the polybasic region (PBR) adjacent to the ING2-PHD is necessary
and sufficient for binding stress-inducible phosphoinositide (PI)
signaling lipids that activate ING2 to promote apoptosis [17]. Of
all ING proteins, ING2 shares highest sequence-homology [18]
and most functional similarities with ING1 [10].
ING1 and ING2 enhance acetylation of p53 on lysine-residues
that are linked to p53-activation [19] and inactivated by hSir2
[20]. Binding of ING1 to p53 was reported to be required for p53-
activity [21] and may prevent binding of the MDM2 ubiquitin E3-
ligase to p53, thereby preventing proteasomal degradation of p53
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21065[22]. However, ING1 also induces apoptosis independently of p53
[23,24]. Hence, whether significant interactions between endog-
enous p53 and ING1 occur in vivo requires clarification.
The ubiquitin-proteasome pathway regulates levels, activity and
location of about 80% of growth-regulatory proteins and
transcription factors with short half-lives [25], such as cyclins,
p21
WAF1 and p53, through a network of ubiquitin-transferring
proteins, ubiquitin E2 and E3-ligases, and proteins regulating their
activity [26]. Most commonly, proteins are polyubiquitinated,
targeting them for rapid degradation by the 26S-proteasome,
while monoubiquitination and multi-monoubiquitination have
been implicated in cellular stress responses, in chromatin
remodeling and in regulating p53-stability [27–30]. Alterations
in ubiquitination are frequent in cancer cells [31]. Various studies
on proteasome-inhibitors in cancer treatment already show
promising results, but it currently remains unclear, why blocking
‘‘non-specific’’ proteasomal degradation induces differential killing
of tumor cells [31]. However, induction of p53-dependent
apoptosis is involved in the selective killing of tumor cells by
certain proteasome-inhibitors [32]. Therefore, identifying mech-
anisms that shield p53 from proteasomal degradation might
contribute to optimized cancer treatment based on selectively
targeting the ubiquitin-proteasome-machinery.
Really Interesting New Gene (RING) finger variants of zinc
finger motifs act as ubiquitin E3-ligases and target proteins
including p53 to the proteasome [33]. Since PHD and RING
finger motifs are both forms of zinc fingers, it was speculated that
some PHDs also act as ubiquitin E3-ligases [34], but closer
inspection of PHD regions did not confirm this hypothesis [35].
Based on this background, and a previous study indicating that
INGs physically interact with at least 16 proteins directly involved
with proteasomal degradation such as regulatory subunits of both
the 20S and 26S-proteasome [8], we asked a) whether ING1
stabilizes p53, and if so, b) whether ING might do this through
affecting ubiquitin metabolism, thereby shielding p53 from
proteasomal degradation.
We discovered a region adjacent to the PHD of ING1 that acts
as a ubiquitin-binding domain (UBD). We also found that
ubiquitin competes with PI signaling lipids for ING1 binding
and that physiological levels of ING1 stabilize monoubiquitinated
forms of the p53 tumor suppressor via its UBD. We also provide
data regarding the mechanism by which the ING1 type II tumor
suppressor stabilizes p53 through a pathway involving the
localization of the herpesvirus-associated ubiquitin-specific prote-
ase (HAUSP), a p53 and MDM2 deubiquitinase (DUB). These
findings could account for the frequently reported activation of
p53 as an inducer of apoptosis by the ING proteins and directly
link lipid stress signaling to ubiquitin-mediated proteosomal
degradation through competition for the polybasic regions found
in ING family proteins.
Results
ING1 expression stabilizes p53
Pilot studies indicated that at levels of sensitivity where physical
interactions were seen between endogenous ING1 and other
proteins [36], those between ING1 and p53 were only observed
when both proteins were overexpressed. Increasing assay-sensitiv-
ity in this study revealed that p53 was specifically recovered in
ING1-immunoprecipitates (IPs) when ING1 was overexpressed,
while p53-overexpression resulted in recovery of p53 in both a-
ING1 and nonspecific preimmune-IPs (Figure 1A). Co-expression
of MDM2 and ING1 did not alter p53-levels recovered in ING1-
IPs compared to expressing ING1 alone, suggesting that ING1
does not compete with MDM2 for p53-binding and so MDM2
does not affect ING1-induced p53 stabilization in this assay.
After co-expression of p53 and ING1, high p53-levels were
recovered in ING1-IPs. This included higher molecular weight
isoforms of p53 (Figure 1A: ‘‘p53 +’’), possibly representing
increased levels of post-translationally modified forms of p53. RT-
PCR showed that ING1 did not increase p53 transcript-levels
(supplementary figure S1). Furthermore, examination of cells
injected with GFP, or GFP and ING1 constructs showed that
ING1 altered nuclear and nucleolar morphology and increased
p53-levels in both nucleus and cytoplasm, primarily in a
perinucleolar pattern (supplementary Figure S2), consistent with
INGs affecting p53 levels [19,37].
ING1 stabilizes p53 at endogenous levels
We next down-regulated ING1 and p53 using siRNA.
Compared to the control (siEGFP), siING1 lines showed consid-
erably lower ING1-levels and a remarkable decrease in p53-levels,
confirming that at endogenous levels, ING1 stabilizes p53. In
contrast, p53-knockdown (sip53) did not affect ING1-levels
(Figure 1B), nor did knocking down ING1 alter p53-levels in cells
with high p53-expression, such as HEK-293 cells containing HPV
E6-stabilized p53 (supplementary Figure S3).
ING1 stabilizes other proteins degraded by proteasome
pathways
To investigate whether ING1 affected levels of other proteins
regulated by the ubiquitin-mediated proteasome pathway, primary
human Hs68 fibroblasts were transfected with the two major
ING1 splicing isoforms, ING1A and ING1b, or treated with the
proteasome-inhibitor lactacystin: ING1b stabilized p53, p21
WAF1
and cyclin D1 as effectively as lactacystin, and MDM2 to a lesser
degree, while ING1a stabilized p21
WAF1 and MDM2, but not p53
or cyclin D1 (Figure 1C). These results are consistent with reports
that ING1b, but not ING1a, collaborates with p53 in biological
assays [37], and that ING1b induces apoptosis while ING1a
induces senescence [5]. Blotting with a-ubiquitin (Ub) showed that
ING1b increased levels of a wider variety of ubiquitinated proteins
than ING1a, exerting effects similar to lactacystin (Figure 1C).
To test if stabilization of p53 was due to altered stoichiometry as
a consequence of ING1-overexpression, ING1b and p53 were co-
expressed (Figure 1D). ING1b-overexpression stabilized high levels
of ectopically expressed wild-type (wt)-p53 and cyclin D1 in the
absence or presence of overexpressed p53, while p21
WAF1 was
slightly higher when both ING1b and p53 were overexpressed.
This is expected since p53 induces P21
WAF1-transcription and
ING1b stabilized both p21
WAF1 and p53. Similarly, MDM2 was
accumulated to a much higher degree when ING1b and p53 were
co-expressed, since it is also transcriptionally induced by p53.
Taken together, ING1b-overexpression increased the levels of
many ubiquitinated proteins. To confirm this effect by an
independent method, cells overexpressing ING1 were stained for
ING1 and Ub: Cells expressing higher levels of ING1 show
markedly elevated levels of Ub (supplementary figure S4).
ING1 stabilizes ubiquitinated forms of p53
To test whether ING1 blocked polyubiquitin-mediated degra-
dation, cells transfected with GFP, GFP and ING1, GFP and p53
or GFP and ING1 and p53 were left untreated or treated with
UV, and lysates were blotted for p53. UV increased p53-levels,
particularly of several p53-variants with lower electrophoretic
mobility (Figure 2A). These variants were of the same mobility as
ones further increased in response to ING1-overexpression. They
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PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21065Figure 1. ING1 stabilizes p53. A) Lysates from 293 cells transfected with the indicated constructs were immunoprecipitated (IP) with preimmune
(Pre-I) or a-ING1 and blotted with the indicated antibodies. Bottom panels confirm protein expression. B) Hs68 cells stably transfected with siEGFP,
siING1b or siTP53 were analyzed for the indicated proteins. C) Lysates from Hs68 or D) from 293 cells transfected with the constructs indicated or
treated with lactacystin (+LC) were blotted with indicated antibodies. Ubiquitin (Ub) visualized by two antibodies gave similar results. MDM2
antibodies typically detected two polypeptides. Abbreviation: CBB-Coomassie-stained loading-controls.
doi:10.1371/journal.pone.0021065.g001
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ubiquitin-moieties bound to a subset of the 20 potential target
lysine-residues of p53 or polyubiquitinated forms of p53. Six of
these 20 lysines are targeted by the MDM2-Ub-ligase which
monoubiquitinates p53 [29,30], and six modified forms of p53
were observed in response to UV and ING1-overexpression
(arrows in Figure 2A). The mobility of the slowest isoform
corresponds to ,100 kDa, consistent with p53 having six
ubiquitin-moieties of 8.541 kDa bound to the six known target-
residues.
To further test the nature of these modified forms of p53, we
compared the multiple bands observed in cells expressing p53 and
ING1 with the p53 forms observed in cells expressing a K48R-Ub
mutant that inhibits poly-ubiquitination of p53, leading to
accumulation of multi-monoubiquitinated proteins that appear
as higher molecular weight forms in SDS-PAGE. His-tagged wt or
K48R mutant Ub plasmid was co-transfected with p53 and
ING1b and ubiquitinated proteins were pulled down using Nickle
(Ni)-NTA agarose beads. The ubiquitinated forms of p53 were
detected by western blotting (WB) (Figure 2B). Cells expressing
either ING1b or K48R-Ub showed very similar bands for p53,
while cells transfected with wt-Ub displayed additional lower
mobility forms of p53 indicative of polyubiquitination. Further-
more, expression of both mutant Ub and ING1b led to increased
levels of unmodified p53 compared to wt-Ub expressing cells
(Figure 2B). This observation further supports the contention that
ING1 acts to prevent the formation of polyubiquitinated forms of
p53, resulting in the accumulation of multimonoubiquitinated and
unubiquitinated forms.
Transfection of ING1 increased p53-levels in cells with wt-, but
not with mutant p53 (supplementary Figure S5). Scanning of blots
and ELISA experiments indicated that ING1b, but not ING1a,
stabilized p53 and increased the overall levels of ubiquitinated
proteins by about three-fold, compared to about four-fold in
response to lactacystin (supplementary Figure S6). To ask if ING1
binds and stabilizes p53 in part via binding Ub, pulldown assays
were performed. ING1b, but not ING1a or p53, bound Ub-
agarose beads (supplementary Figure S7). Binding was specific
since ING1b did not bind agarose bead negative controls. Re-
probing showed that p53 was also recovered by Ub-agarose beads,
but only in cells overexpressing ING1b. This indicates the
formation of Ub-ING1b-p53-complexes, since p53 was not seen
in the absence of ING1b-overexpression.
Given that the ING2-PHD was required for activating p53 [17],
we next examined if an ING1-carboxyl-terminal deletion (remov-
ing the PHD and adjacent PBR) stabilized unmodified and/or
monoubiquitinated p53. Wt-, but not the deleted form of ING1
stabilized both endogenous (Figure 3A) and ectopically expressed
p53 (Figure 3B) to a degree comparable to the effect of the
proteasome-inhibitor MG132.
ING1 contains a ubiquitin-binding domain (UBD)
adjacent to its PHD
Since ING1 promoted accumulation of ubiquitinated forms of
p53, we examined the ING1 protein sequence for motifs known to
be involved in Ub-binding [38]. We identified a UBD adjacent to
the ING1 PHD (supplementary Figure S8), which was previously
described as a PBR, necessary and sufficient for the binding of PIs
[17]. Nuclear magnetic resonance (NMR) analysis has shown that
UBD binding can block access to the K48 residue of Ub, thereby
blocking polyubiquitination that targets proteins to the proteasome
[39]. Given that several proteins affecting proteasomal pathways
contain UBDs, this suggested a role for ING1 in regulating p53
stability through this pathway.
ING1 does not stabilize p53-mutants lacking sites of
ubiquitination
To ask if ING1-mediated stabilization of p53 was Ub-
dependent, a Histidine (His)6-Ub construct was co-expressed in
H1299 (p53-/-) cells with wt- and mutant forms of ING1, and with
Figure 2. ING1 stabilizes ubiquitinated forms of p53. A) Lysates
of Hs68 cells infected with the constructs indicated were exposed to UV
(25 J/m
2) and blotted with a-p53. Arrows: ubiquitin-conjugated forms of
p53 (p53-Ub) induced by UV and stabilized by ING1b expression. Lower
panels confirm ING1b expression and protein loading (CBB). B) HEK293
cells were transfected with the expression constructs indicated and
grown for 24 hours. Cells were then lysed, lysates were clarified by
centrifugation and lysates were incubated with Nickle (Ni)-NTA agarose
beads. Beads were washed, eluted with imidazole and eluates were
resolved using SDS-PAGE. After transfer to membranes p53 protein was
detected by western blotting (WB). The input samples from cell lysates
that were used for the pull downs confirm that equal amounts of
lysates were used with the actin loading control and also were used to
determine the levels of ING1 and p53.
doi:10.1371/journal.pone.0021065.g002
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are targets of ubiquitination [39], mutated to arginine). Wt-ING1
and MDM2, but not ING1 lacking the PHD and UBD
(ING1b
del(PHD-UBD)), promoted the formation and/or stabilization
of similar ubiquitinated forms of p53 (arrows in Figure 4A). In
contrast, p53K6R was not affected by ING1 or MDM2. Wt-, but
not mutant ING1 stabilized wt-p53, but not p53K6R, by several-
fold (Figure 4A, B).
The PHD and UBD of ING1 stabilize forms of modified
p53 similar to those produced by MDM2
IP-Western analysis showed that wt-, but not ING1b
del(PHD-UBD)
stabilized the same six ubiquitinated forms of p53 as produced by
the MDM2 Ub-E3 ligase (Figure 4C, top panel, lanes 2,5). An
ING1-mutant lacking the PHD, but containing an intact UBD,
gave only partial stabilization of p53 suggesting a contextual
requirement for UBD-activity as previously reported for other
UBDs [38]. While corroborating nickle-agarose experiments, this
assay favored recovery of p53 with one or two Ub-moieties. This
may be due to multiple monoubiquitination interfering with the
binding of the p53 monoclonal antibody used, since both the
ubiquitination sites and the antibody recognition site are located in
the carboxyl region of p53.
Wt-ING1 stabilized both ubiquitinated and non-ubiquitinated
forms of p53 (Figure 4C, lane 2), while MDM2 only increased
levels of p53 monoubiquitinated on several residues (Figure 4C,
top panel, lane 5), but failed to promote accumulation of non-
ubiquitinated p53 (Figure 4C, third panel, lane 5). This implies
that MDM2 promoted multiple monoubiquitination of p53 with
subsequent polyubiquitination of residues by p300 resulting in
proteasomal degradation [28], while ING1 promoted stabilization
of both monoubiquitinated and non-ubiquitinated forms of p53,
consistent with data in Figure 2B. Furthermore, while the UBD
seemed to be primarily responsible for interacting with Ub,
binding to unmodified forms of p53 was dependent on the
function of at least three regions of ING1: the NLS, the PHD and
the UBD (Figure 4C, lanes 3,4) - regions flanking the 14-3-3
binding site on serine 199 of ING1 that promotes 14-3-3-mediated
export of the ING1 protein to the cytoplasm [40]. Consistent with
these data, co-expression of wt- and PHD-UBD-deleted forms of
ING1 with wt-p53, or with the p53K6R-mutant, followed by IP-
western-analysis using ING1 antibodies, revealed a strong
interaction of wt-ING1 with wt-p53 and a weak one with
p53K6R (supplementary Figure S9). Blotting for ING1 and p53
showed that higher levels of mutant ING1 were expressed
revealing the difference in binding affinity even more.
ING1 bound ubiquitinated forms of p53 through its PHD-UBD
region and induced the accumulation of similar ubiquitinated
forms of p53 as did UV (Figure 2A), expression of ubiquitin K48R
(Figure 2B), the proteasome-inhibitor MG132 (Figure 3A, B) and
MDM2 (Figure 4A), suggesting that it stabilized p53 that was
monoubiquitinated on particular lysine residues. If so, then mutant
p53, that could not be ubiquitinated on these residues, while being
inherently stable, would not be further stabilized by ING1, which
was the case in this study (lower panels of supplementary Figure
S9, lanes 1 and 2 compared to lanes 4 and 5).
ING1 binds and acts through HAUSP to affect p53-levels
Several Ub-E3 ligases and deubiquitinases (DUBs) can affect
p53 stability, and HAUSP (also known as USP7) can bind to and
affect the stability of both MDM2 and p53 [30]. To identify the
different potential regulators of p53-activity affected by ING1,
ING1-IPs were examined for the presence of HAUSP: Endoge-
nously expressed HAUSP was indeed recovered in ING1-
immunoprecipitates and the reciprocal IP-western confirmed their
interaction (Figure 5A). If such interaction served to target
HAUSP to p53 and retain it in a non-polyubiquitinated state,
then HAUSP should be necessary for stabilization of p53 by
ING1. To test this idea, ING1 was transfected into cells in the
presence of HAUSP expression constructs or two different
HAUSP siRNAs. As shown in Figure 5B, cells expressing ING1
showed higher p53-levels, cotransfection with HAUSP slightly
increased this effect while two different siRNAs targeting HAUSP
completely blocked the ability of ING1 to stabilize endogenous
p53. The average p53-levels from two independent experiments
under these conditions are shown in Figure 5C. Similar results, but
of a greater magnitude were observed with overexpressed p53 in
HEK293 cells as shown in Figure 5D. The absolute degree of p53-
increase in response to ING1 was not as great as seen in previous
experiments, since these data reflect a more modest transfection
efficiency. Nevertheless, cotransfection of ING1 with both siRNA-
species would only detect transfected cells and showed complete
blockage of ING1-induced p53 stabilization.
Figure 3. Discovery of a region adjacent to the ING1b-plant
homeodomain (PHD) that acts as a ubiquitin-binding domain
(UBD). A) Lysates from Hs68 cells treated or transfected as
indicated and blotted for p53. Lower panels confirm ING1-
expression and loading. B) Cells treated as in A), but also co-infected
with p53-adenovirus, were blotted as in A). Abbreviations: CBB:
Coomassie-stained loading-controls; GFP: green fluorescent protein,
ING1b
del(PHD-PBR): ING1b-construct with PHD-PBR deletion, PBR: polybasic
region, wt-wild-type.
doi:10.1371/journal.pone.0021065.g003
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SincetheUBDweidentifiedwasrecentlydescribedasa PBR that
was necessary and sufficient for binding of PIs [17], we asked
whether Ub competes for ING1-binding with monophosphorylated
lipid species previously shown to bind ING2 [17,41]. We found that
full-length ING1 had a marked preference for binding the same
phospholipids (PI(3)P, PI(4)P, PI(5)P) as previously reported for the
isolated PBR of ING2 [17] (Figure 6A). Also, Ub showed dose-
dependent inhibition of ING1b-binding to lipids. That was not
observed with control peptides (insulin). Results from three
independent surface plasmon-resonanceexperimentsgave apeptide
dissociation constant (Kd) for Ub-ING1b-binding of ,100 nM
(Figure 6B), suggesting slightly more avid binding than reported for
ING-PHD-histoneH3peptideinteractionsthat variedfrom1.5 mM
to 2.3 mM depending on the histone methylation state [12].
Discussion
In this study, we identified the PBR adjacent to the ING1-PHD
as a novel UBD. We also showed that the PHD and UBD of ING1
stabilize the same forms of p53 that are stabilized by DNA-damage
or by proteasome-inhibitors. These also co-migrate with mono-
ubiquitinated forms of p53, generation of which by the Ub-E3
ligase MDM2 results in relocalization of p53 rather than
proteasomal degradation [29,30]. Based on these data and the
significant role of proteins with UBDs in various processes such as
the DNA-damage-response [39], this study suggests a role for
ING1 in increasing the proapoptotic functions of p53, and thus a
new model of stress-induced p53-activation.
In this model (Figure 7), non-ubiquitinated p53 is produced
continually and monoubiquitinated on multiple lysine-residues by
MDM2. The p300/E4-ligase then elongates Ub-chains and targets
p53 to the proteasome [28]. UV and other stresses induce ING1b-
bindingtop53inan Ub-facilitatedmanner,helping to target ING1-
associated HAUSP to p53, thereby stabilizing p53 due to HAUSP-
mediated deubiquitination of nascent polyubiquitin chains. Co-
localization of ING1 and p53 also promotes acetylation of p53
(p53ac) by ING on lysine-residue 382 [19,42], which subsequently
activates p53 as a transcription factor. UV also induces the
formation of bioactive stress-signaling PIs [42,43] that bind ING1
and ING2 on a site overlaping the Ub-binding-site [17]. PIs may
subsequently competitively displace Ub and trigger the release of
free p53 at high local concentrations that favor multimerization to
induce p53-DNA-binding [44]. ING1-bound monoubiquitinated
p53 could also be transported to the cytoplasm via 14-3-3-mediated
cytoplasmic relocalization of ING1 [40], where p53 directly affects
mitochondria-based apoptosis [45-48].
Figure 4. ING1b does not stabilize p53-mutants lacking sites of
ubiquitination. A) H1299 cells transfected as indicated were blotted
for p53 following nickel-agarose-precipitation and in vivo ubiquitina-
tion. Arrows: ubiquitinated species of p53 (Ub-p53). Lower four panels
confirm indicated protein-expression and protein loading (actin). B)
Fold-changes of mean p53 levels after co-expression of indicated forms
of p53 and ING1b (three independent assays scanned by densitometry).
Error bars: standard deviations. C) H1299 cells were co-transfected as
indicated and lysates immunoprecipitated using p53-antibody linked to
Protein-A-agarose. Precipitates were blotted using a-His. Lower four
panels confirm p53-, MDM2- and ING1b-expression and protein
loading (actin). Abbreviations: ING1b
del(PHD-PBR): ING1b-construct with
PHD-PBR-deletion; ING1b
del(NLS): ING1b-construct with NLS-deletion;
ING1b
del(PHD-UIM): ING1b-construct with PHD-UIM-deletion; p53(K6R):
p53 containing six ubiquitinated lysine-residues that are targets for
ubiquitination (Lys367, Lys369, Lys370, Lys378, Lys379, and Lys383)
mutated to arginine; NLS: nuclear localization-sequence; PBR: polybasic
region; PHD: plant-homeodomain; UIM: ubiquitin-interacting motif; wt:
wild-type.
doi:10.1371/journal.pone.0021065.g004
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21065While this model predicts that ING1 stabilizes p53, no
induction or stabilization of ING1 mRNA or ING1-protein by
p53 would be predicted, as noted (supplementary Figure S1) and
previously reported [49]. This model is supported by the
competition between PIs and Ub for ING1b-binding, providing
direct evidence that INGs can link stress-induced PI-signaling to
Ub-mediated protein metabolism. It also indicates that ING1b-
mediated stabilization and translocation of p53 to the cytoplasm
and subsequently to the mitochondria, but not activation of
Figure 5. ING1 binds and acts through the herpesvirus-
associated ubiquitin-specific protease (HAUSP) to affect p53-
levels. A) HEK293 cells were harvested and immunoprecipitated (IP) as
indicated and with controls (rabbit pre-immune sera for HAUSP or
mouse anti-GST for ING1). IPs were blotted for HAUSP (USP7) or ING1. B)
HEK293 cells were transfected as indicated, including two different
HAUSP-siRNAs (Si1, Si2). C) Results from experiments such as the one
shown in B) were scanned by densitometry. Columns: average of two
independent values with p53-levels in untransformed cells set to 1.0.
Relative p53-values represent levels seen in both transfected and
untransfected cells in panels B) and C). D) HEK293 cells cotransfected
with p53 and HAUSP in the absence and presence of two different
HAUSP siRNAs.
doi:10.1371/journal.pone.0021065.g005
Figure 6. The ING1b carboxyl region competitively binds
phospholipids and ubiquitin. A) Phosphatidylinositol-phosphate
(PI-P) strips containing lysophosphatidic acid (LPA), lysophosphocholine
(LPC), phosphatidylinositol (PI), PI(3)P, PI(4)P, PI(5)P, phosphatidyletha-
nolamine (PE), phosphatidylcholine (PC), sphingosine 1-phosphate
(S1P), PI(3,4)P2, PI(3,5)P2, PI(4,5)P2, PI(3,4,5)P3, phosphatidic acid (PA),
phosphatidylserine (PS), and a blank spot in the shown configuration.
Purified GST-ING1b plus insulin (negative control) or Flag-ubiquitin with
the concentrations indicated were co-incubated with PI-P-strips and
protein-lipid blot assays were performed to detect bound GST-ING1b
using a-ING1. Three independent experiments gave similar results. B)
Surface plasmon resonance analyses of full-length GST-ING1b binding
to immobilized FLAG-ubiquitin.
doi:10.1371/journal.pone.0021065.g006
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which ING proteins might potentiate p53-mediated apoptosis.
Identifying the individual contributions of ING1-binding to the
proteins listed at http://www.visualgenomics.ca/gordonp/S2.
html [8] that are known to regulate proteasomal activity will
further clarify the basis of Ub-dependent stabilization of p53.
Given that ING1 is down-regulated in many human malignan-
cies [2,3], this model implies ING1 as a prognostic factor for
response to targeted cancer therapy: patients with tumors
expressing low ING1-levels might not significantly profit from
certain proteasome-inhibitors or other anticancer agents, that
involve the induction of p53-dependent apoptosis in the selective
killing of tumor cells.
Materials and Methods
Cell culture
Hs68 (ATCC CRL-1635; wild-type (wt)-TP53), 293 (ATCC
CRL-10852) and H1299 cells (ATCC CRL-5803; TP53-/-) were
obtained from ATCC. U251 (mutant TP53) and HCT116 (wt-
TP53) cells were from P. Forsyth and B. Vogelstein, respectively.
Hs68, 293, and U251 cells were grown as described [50]. HCT116
cells were grown in McCoy’s 5a with 1.5 mM L-glutamine, 10%
FCS. H1299 cells grew in RPMI containing 10% FBS. Cells were
maintained at 37uC in 95% air and 5% CO2. UV-treatment was
done in the absence of medium after which media, in which pre-
exposed cells were growing, were replaced. All cell lines and strains
tested negative for mycoplasma.
DNA constructs, transfection and infection
ING1a, ING1b, ING2 and TP53 were subcloned into pAdTrack-
CMV containing a separate EGFP expression cassette and
recombined with ‘‘pADEasy’’-1 in BJ5183-E. coli. Recombinants
were re-amplified in XL-Blue, linearized (PacI) and transfected
into 293 cells for packaging. Viral clones were selected for
expression, plaque amplified and purified over CsCl2. The ING1,
TP53 and MDM2 genes were cloned in pCI (Clonetech). ING1
deletions were generated by one-step-PCR. Optimized adenoviral
infections were done at multiplicities of infection (MOI) of 100 for
Hs68, 20–50 for U251 and HCT116 cells giving ,95% infectivity
as monitored by green fluorescent protein (GFP) expression. No
toxicity was observed when adenoviruses were used at the MOIs
indicated. Transient transfections of plasmids were performed
using a modified calcium phosphate method for 293 and H1299
cells.
Small interfering (si)RNA
Multiple splicing isoform-specific siRNAs to ING1b and EGFP
(negative control) were designed and cloned into psilencerU6
(Ambion). Constructs were used to generate stable lines in
HCT116 cells. After multiple passages, lines were tested for gene
expression using RT-PCR primers (sequences available upon
request) for p53, ING1 and control RNAs (GAPDH or b-actin).
Microinjection and indirect immunofluorescence
Hs68 cells synchronized in G1 were microinjected as described
[50]. Constructs encoded GFP or GFP and ING1. Cells were fixed
24h after injection and stained for p53 with a mixture of DO1,
PAb240 and PAb421 monoclonal antibodies and with secondary
Cy-3 fluorescent antibodies (Amersham) for 1h at 37uC.
Western and immunoprecipitation (IP)–western assays
Cells were infected or transfected with the adenoviral constructs
or plasmids encoding p53, ING1, MDM2 and two vector controls.
Cells were treated with 8 mM lactacystin for 6h, with 30 mM
MG132 for 4 h or with 15 mM MG132 for 16 h (Calbiochem) as
indicated. After cell lysis, samples were blotted with anti(a)-p53
(Santa Cruz-6243), a-cyclin D1 (Cell Signalling-2926) or a-cyclin
A polyclonal (Santa Cruz-751), a-MDM2 (Santa Cruz-812) or a-
ubiquitin (a-Ub) monoclonal (Santa Cruz-9133), a-Histidine (a-
His-6) (Santa Cruz-803), a-p21
WAF1 polyclonal (Santa Cruz-397),
a-actin polyclonal, a-p27 monoclonal, a-herpesvirus-associated
ubiquitin-specific protease (a-HAUSP) (Bethyl Laboratories), a-
ING1 monoclonal and a-ING1b isoform-specific polyclonal
antibodies (Southern Alberta Cancer Research Institute (SACRI)
Antibody Services). Information regarding the particular epitope(s)
recognized by the different ING1 antibodies is provided in Suzuki
et al., 2011 [51]. In UV-experiments, Hs68 cells were exposed to
30 J/m
2 of UV 18 h post-infection and harvested 12 h after UV.
IP-westerns were done as described [11].
RT-PCR
Hs68 cells were harvested 24 h post-infection and extracted for
RNA using Trizol (Invitrogen). DNAse treatment preceded
confirmation of RNA quality by absorbance, visual inspection
(1% denaturating agarose gel electrophoresis and EthBr staining)
and RT-PCR for GAPDH. cDNA samples were used to estimate
relative TP53-, P21
WAF1-, MDM2-, CyclinD1- and ING1-levels by
comparison to internal controls (GAPDH, b-actin) (primer-sequenc-
es available upon request). Aliquots of PCR products equalized to
give equivalent signals from the internal control mRNAs were
electrophoresed through 2% agarose gels (Pharmacia), stained
with 0.2 mg/ml EthBr, analyzed by computerized densitometric
scanning of the images (Kodak imaging software) and normalized
using internal controls.
Figure 7. A model for the stabilization and activation of p53 by
ING1b. Data presented in this study support a model in which p53 is
continually expressed, monoubiquitinated on up to six different lysine
residues and then is rapidly targeted for proteosomal degradation by
polyubiquitinization through K48 residues by the p300/E3-ligase. Under
conditions of stress ING1 is relocalized by binding phosphatidylinositol-
5 monophosphate which can then be replaced by binding ubiquitin
(Ub) located on p53. ING1 either imports, or subsequently binds
herpesvirus-associated ubiquitin-specific protease (HAUSP) to prevent
or reverse the polyubiquitination of mono- or multimonoubiquitinated
forms of p53, thereby stabilizing these and also unubiquitinated forms
of p53 to promote either transcriptional activation or mitochondrial-
mediated apoptosis.
doi:10.1371/journal.pone.0021065.g007
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All sequences used were from NCBI and multiple alignments
were done (EMBL Clustal-W-program) (sequence accession
numbers available upon request).
Ubiquitin (Ub) pull-down assays
HCT116 cells infected with adenovirus or transfected with
plasmids were harvested at +24 h and lysed in NP-40-buffer.
Lysates were incubated with Ub-agarose (Biochem) or Protein A-
agarose beads (Pharmacia; negative control) for 4 h at 4uC. Beads
were washed briefly and proteins were solubilized in SDS-buffer,
electrophoresed and blotted with a-ING1 monoclonals or a-p53
polyclonal antibodies. To analyze p53 ubiquitination, HEK293
cells were transfected with plasmids encoding p53, ING1, His-wt-
Ub and His-K48R Ub and grown for 24 hours. They were then
lysed and the cleared lysate incubated with Nickle (Ni)-NTA
agarose beads (Qiagen) for one hour. The beads were then washed
and proteins eluted with 500 mM imidazole. They were then
resolved using SDS-PAGE and p53 was detected by western
blotting.
In vivo ubiquitination assay
H1299 cells were transfected with 1 mg wt-p53 or p53-K6R
constructs or with 2 mg each of the different INGs, MDM2 (positive
control), and His6-tagged-Ub. Purification of His-6-ubiquitinated
conjugates was done as described [29]. 36 h after transfection,
cells were washed twice with PBS and harvested. 20% of each
suspension was used for protein staining and western blots, the rest
for isolation of ubiquitinated conjugates.
Lipid binding and lipid-ubiquitin competition assays
Protein-lipid blot assays were done as described [43]. For
competition assays, the indicated control (insulin) or competitor
(ubiquitin) polypeptides were incubated with GST-tagged affinity
purified ING1 prior to incubation with phosphatidylinositol-
phosphate (PIP) strips (Echelon Bioscience) at 4uC . Bound ING1
was visualized using a-GST.
Surface plasmon resonance (SPR)
Binding experiments were done by the SACRI Antibody
Facility on a Biacor 3000 biosensor at 25uC. Recombinant
FLAG-ubiquitin (Boston Biochem) was immobilized on CM-5
chips by amine cross-linking, increasing amounts of recombinant
GST-ING1 were injected at 30 ml/min and SPR-response was
recorded. Sensograms were obtained by subtracting signals from
the reference surface (blank) from the signal obtained from the
FLAG-ubiquitin surface. Binding assays were repeated thrice.
After curve fitting and averaging, results were obtained from both
steady-state affinity and kinetic data.
Supporting Information
Figure S1 RT-PCR using GAPDH or actin as internal amplifi-
cation controls was performed to estimate TP53-, P21
WAF1-,
ING1b-, MDM2-,o rCyclin D1-mRNA-levels in Hs68 fibroblasts
transfected with the indicated constructs. Bar-graph: mean-mRNA-
levels of three independent experiments, setting green fluorescence
(GFP; negative control) to zero. Error bars: standard deviations.
(TIF)
Figure S2 Hs68 fibroblasts injected with the indicated constructs
were stained for DNA (DAPI) and p53. Green fluorescence (GFP)
identifies injected cells. Arrows: nucleolar morphology in the
absence and presence of elevated ING1b. p53 levels were elevated
in 55 of 60 cells examined and localization was nuclear,
perinuclear and cytoplasmatic. Bar = 10 mm.
(TIF)
Figure S3 HEK293 cells transfected with the indicated siRNAs
were analyzed for p53, ING1b and actin levels.
(TIF)
Figure S4 ING1b-transfected Hs68 cells were stained for DNA
(DAPI), ING1 and ubiquitin (Ub). The arrow highlights a
transfected cell.
(TIF)
Figure S5 Lysates from cells with wild-type (wt; Hs68) or mutant
(U251; containing the p53R273H mutation) p53 infected with the
indicated constructs were blotted for p53. CBB-lanes: Coomassie-
stained loading controls. Green fluorescence (GFP) indicated
infection efficiencies of .95% in all cases.
(TIF)
Figure S6 Dot-blot dilution series of lysates from Hs68
fibroblasts treated for 12h with lactacystin (+LC) or left untreated
(-LC) served as positive and negative controls, respectively, for
lysates from cells infected with the adenoviral constructs indicated.
Blots were probed with ubiquitin (Ub) antibodies. Signals from
three independent ELISA experiments using Hs68 fibroblasts were
quantitated by scanning densitometry and plotted. Error bars:
standard deviations.
(TIF)
Figure S7 Lysates of HCT116 cells (TP53 -|-) infected with the
indicated constructs were incubated with ubiquitin (Ub)-conjugat-
ed agarose or agarose beads only (negative control). Precipitates
were analyzed by western blotting with a-ING1 or a-ING1 plus a-
p53 antibodies. Lower panel: western blot confirming ING1 and p53
protein expression. Control (C)-lanes: precipitates from untrans-
fected cells. GFP: green fluorescence protein.
(TIF)
Figure S8 Sequence alignment of the conserved (common)
region of ING1b with a group of four representative PHD proteins
and four proteins that contain a ubiquitin-binding-domain (Clustal
W program (18)). Abbreviations: PIP: PCNA-interacting-protein-
domain; LID: Lamin-interaction-domain; PHD: plant-homeodo-
main; UBD: ubiquitin-binding-domain; UIM: ubiquitin-interact-
ing-motif; NLS: nuclear localization-sequence; NTS: nucleolar
targeting-sequence. Bar height: degree of conservation of the
C4HC3-residues of the PHD and EL/M ALSE-residues of the
UIM.
(TIF)
Figure S9 Lysates of H1299 cells co-transfected with wild-type
(wt) or the K6R-mutant of p53 and either vector (V), wild-type
ING1b (wt) or ING1b with a deletion at the ubiquitin-interacting-
motif (UIM) of its plant homeodomain (PHD) (ING1b
del(PHD-UIM))
were precipitated with a-p53 and a-ING1 monoclonal antibodies
crosslinked to Protein-G-Sepharose. Precipitates were analyzed by
blotting using a mixture of a-p53 and a-ING1. Lower panels:
western blots with 0.5% of the lysates used in the upper panels to
determine expression levels of p53 and protein loading (actin).
(TIF)
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